Stockscreener 앱 받기
7.95
2.45%
-0.20
Cervomed Inc 주식(CRVO)의 최신 뉴스
Trend analysis for CervoMed Inc. this weekJuly 2025 Market Mood & Scalable Portfolio Growth Ideas - newser.com
Will CervoMed Inc. stock reach all time highs in 2025Market Rally & Reliable Breakout Forecasts - newser.com
Statistical indicators supporting CervoMed Inc.’s strengthJuly 2025 EndofMonth & Real-Time Market Sentiment Alerts - newser.com
Custom watchlist performance reports with CervoMed Inc.Stop Loss & Accurate Entry/Exit Alerts - newser.com
Analyzing recovery setups for CervoMed Inc. investors2025 Risk Factors & AI Based Trade Execution Alerts - newser.com
Is CervoMed Inc. a candidate for recovery playJobs Report & Free Technical Pattern Based Buy Signals - newser.com
What to do if you’re stuck in CervoMed Inc.2025 Momentum Check & Community Supported Trade Ideas - newser.com
Does CervoMed Inc. stock trade at a discount to peersIPO Watch & Advanced Swing Trade Entry Plans - newser.com
How to interpret RSI for CervoMed Inc. stockMarket Volume Summary & Stepwise Entry/Exit Trade Alerts - newser.com
Will CervoMed Inc. outperform the market2025 Earnings Impact & Low Volatility Stock Recommendations - newser.com
Using data tools to time your CervoMed Inc. exitJuly 2025 Selloffs & High Yield Equity Trading Tips - newser.com
Advanced analytics toolkit walkthrough for CervoMed Inc.2025 Geopolitical Influence & Long Hold Capital Preservation Plans - newser.com
CervoMed (NASDAQ:CRVO) Receives Sell (D-) Rating from Weiss Ratings - MarketBeat
Why CervoMed Inc. stock is rated strong buyShare Buyback & Low Drawdown Momentum Ideas - newser.com
CervoMed Unveils Promising Phase 2b Trial Results - TipRanks
CervoMed Drug Cut Dementia Progression Risk By 75% In Trial - inkl
CervoMed shares jump after strong results in dementia drug trial - MSN
CervoMed stock jumps after new positive dementia drug results - Business Upturn
CervoMed stock soars after positive dementia treatment trial data - Investing.com
CervoMed Says Neflamapimod Shows Effective in Treating Dementia with Lewy Bodies Without Alzheimer's Overlap - MarketScreener
CervoMed (CRVO) Reveals Promising Phase 2b Trial Data for Dement - GuruFocus
CervoMed Inc. Reports Promising Phase 2b Trial Results for Neflamapimod in Dementia with Lewy Bodies - Quiver Quantitative
1.12‑pt CDR‑SB gain; 50% GFAP drop — CervoMed Phase 2b RewinD‑LB data show clinical–biomarker correlation - Stock Titan
CervoMed appoints Matthew Winton as chief commercial and business officer By Investing.com - Investing.com Canada
CervoMed Appoints Matthew Winton, Ph.D., as Chief Commercial and Business Officer - GlobeNewswire
CervoMed Inc. Appoints Matthew Winton as Chief Commercial and Business Officer - MarketScreener
CervoMed appoints Matthew Winton as chief commercial and business officer - Investing.com
CervoMed appoints Matthew Winton, Ph.D., as chief commercial and business officer - MarketScreener
75K-option grant: CervoMed names Matthew Winton Chief Commercial & Business Officer, readies for Phase 3 - Stock Titan
CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference - Sahm
Applying chart zones and confluence areas to CervoMed Inc.Trade Volume Summary & Daily Chart Pattern Signals - newser.com
Will CervoMed Inc. stock go up soon2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Will CervoMed Inc. (DP8) stock keep high P E multiples2025 Price Action Summary & Step-by-Step Trade Execution Guides - newser.com
Short Interest in CervoMed Inc. (NASDAQ:CRVO) Decreases By 31.7% - MarketBeat
What drives CervoMed Inc stock priceEarnings Revision Updates & Free Stock Education Platform for New Investors - earlytimes.in
How CervoMed Inc. (DP8) stock compares with market leaders2025 Trade Ideas & Consistent Growth Equity Picks - newser.com
Can a trend reversal in CervoMed Inc. lead to recoveryJuly 2025 Setups & Expert-Curated Trade Recommendations - newser.com
Is CervoMed Inc. stock a buy in volatile markets2025 Dividend Review & Short-Term High Return Ideas - newser.com
Live market analysis of CervoMed Inc.Market Risk Analysis & Free Real-Time Market Sentiment Alerts - newser.com
1.24%
자본화:
|
볼륨(24시간):